ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1123

Targeted Mutations Identify the Active Site of Glucocorticoid-Induced Leucine Zipper (GILZ)

Huapeng Fan1, Die Wang2, Qiang Cheng3, James Harris3, Sarah Jones3, Yuan Hang Yang4 and Eric Morand4, 1Lupus Research Group, Center for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Calyton, Australia, 2Hudson Institute of Medical Research, Clayton, Australia, 3Lupus Research Group, Center for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Australia, 4Lupus Research Group, Center for Inflammatory Diseases, School of Clinical Sciences at Monash Health, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Australia

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: glucocorticoids, inflammation and macrophages

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Glucocorticoids (GC) have been used to treat inflammatory disease for more than six decades, but the broad spectrum of therapeutic effects is accompanied by significant metabolic adverse effects. Recent studies suggest that glucocorticoid-induced leucine zipper (GILZ) mimics the anti-inflammatory effects of GC, including inhibiting the activation of macrophage, B cells, Th1 and Th17 cells, but lacks GC adverse effects. However, little is known about molecular mechanisms of GILZ action that could empower drug discovery.

Methods:

Expression of GILZ and acetylated GILZ was measured by Western blotting in murine bone marrow-derived macrophages. WT and mutated GILZ plasmids were co-transfected with an NF-κB luciferase reporter into human microvascular endothelial cells (HMECs). IL-6 and MCP-1 were measured by ELISA. NF-κB activity was measured using a NF-κB luciferase reporter assay. Interactions between GILZ and p65/NF-κB were detected by Fluorescence lifetime imaging (FLIM)/ Fluorescence Resonance Energy Transfer (FRET).

Results: GILZ acetylation was detected in macrophages, and TSA, a deacetylase inhibitor, increased GILZ acetylation in a time-dependent manner. WT GILZ was constructed in the pcDNA3.1 expression plasmid and overexpression of GILZ significantly inhibited NF-κB activity and IL-6 and MCP-1 expression. Using an acetylation substrate-binding site alignment approach, we predicted three potential GILZ acetylation sites at K37, K77 and K108. Acetylation of GILZ was lost when K77, but not K37 or K108, was mutated to arginine (K77R). Mutation at K77 aborgated GILZ inhibition of NF-κB activity, and IL-6 and MCP-1 expression. Co-IP and FLIM/FRET demonstrated that GILZ mutation at K77 prevented interaction with p65/NF-κB.

Conclusion: Acetylation of GILZ at K77 is required for its interaction with NF-κB and anti-inflammatory effects. This suggests a potential target for enhancing the anti-inflammatory effects of GILZ as a GC mimic via inducing K77 acetylation.


Disclosure: H. Fan, None; D. Wang, None; Q. Cheng, None; J. Harris, None; S. Jones, None; Y. H. Yang, None; E. Morand, None.

To cite this abstract in AMA style:

Fan H, Wang D, Cheng Q, Harris J, Jones S, Yang YH, Morand E. Targeted Mutations Identify the Active Site of Glucocorticoid-Induced Leucine Zipper (GILZ) [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/targeted-mutations-identify-the-active-site-of-glucocorticoid-induced-leucine-zipper-gilz/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/targeted-mutations-identify-the-active-site-of-glucocorticoid-induced-leucine-zipper-gilz/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology